Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Biomarin Pharmaceutical (BMRN) and maintained a $100 price target.
February 23, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Biomarin Pharmaceutical with a $100 price target.
The reiteration of an Overweight rating and maintenance of a $100 price target by a reputable analyst firm like Cantor Fitzgerald could positively influence investor sentiment towards BMRN, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90